WYE-125132

WYE-125132

CAT N°: 18372
Price:

From 55.00 46.75

The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that is central to two protein complexes, mTORC1 and mTORC2. These complexes are differentially regulated (e.g., only mTORC1 is sensitive to rapamycin (Item No. 13346)) and regulate different pathways. WYE-125132 is an ATP-competitive inhibitor of mTOR (IC50 = 0.19 nM) that inhibits signaling through both mTORC1 and mTORC2.{29888} It is selective for mTOR over phosphatidylinositol 3-kinase isoforms.{29888} WYE-125132 is effective against mTORC1 and mTORC2 in diverse cancer models, both in vitro and in vivo.{29888} Oral administration of WYE-125132 alone blocks mTOR signaling and prevents tumor growth in breast, lung, renal, and glioma cancer xenografts in mice, while combination therapy with the VEGF-inhibitor bevacizumab causes complete regression of A498 renal carcinoma tumors.{29888} In addition to its applications in cancer, WYE-125132 has been used to delineate novel aspects of mTOR signaling.{29887}

We also advise you